Aim: Visceral leishmaniasis (VL) caused by parasites belonging to genus Leishmania (L.) is classified as a category I disease by the TDR/WHO. The understanding of the pathogenesis of this disease was built from the findings of available experimental models. Among all available models, the Syrian hamster (Mesocricetus auratus) is the most suitable model for the experimental representation of VL. In this review, we have focused on the opportunities and challenges of using the hamster as an experimental model for visceral leishmaniasis.
Methods: The studies referenced in this review were based on searches in PubMed and Google Scholar without a specific timeline. We collected study results underlining the clinicopathological response, immunopathogenesis and factors determining the outcome of VL in hamsters. Particular emphasis was given in the context of developing new therapeutics and testing potential candidates for vaccine development.
Conclusion: Among all animal models, M. auratus is undoubtedly a better animal model for immunopathogenesis, drug discovery and vaccine development studies of VL infection. But, further optimization of this animal model is required to mimic human VL completely.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pim.12768 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!